U.S. market Open. Closes in 5 hours 5 minutes

LFCR | Lifecore Biomedical, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 7.15 - 7.99
52 Week Range 3.68 - 8.90
Beta 0.90
Implied Volatility 104.75%
IV Rank 18.40%
Day's Volume 120,154
Average Volume 244,979
Shares Outstanding 36,827,000
Market Cap 268,468,830
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 1996-02-15
Valuation
Profitability
Growth
Health
P/E Ratio 56.08
Forward P/E Ratio N/A
EPS 0.13
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 524
Country USA
Website LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
*Chart delayed
Analyzing fundamentals for LFCR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see LFCR Fundamentals page.

Watching at LFCR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LFCR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙